While unconjugated hyperbilirubinemia is associated with the use of ritonavir-boosted atazanavir (ATV/r), the nature of the hyperbilirubinemia over time and its clinical significance has not been well-characterized in controlled studies. The purpose of this study is to describe the patterns and clinical significance of hyperbilirubinemia in patients treated with ATV/r in the CASTLE study.
Methods
CASTLE was a randomized, 96-week study to assess the efficacy and safety of ATV/r vs. lopinavir/r, each with tenofovir/emtricitabine, in treatment-naïve patients. This analysis included only ATV/r patients. The proportions of patients with hyperbilirubinemia (grades 3-4 total bilirubin elevation) were tabulated for each study visit. The impact of hyperbilirubinemia on symptoms (jaundice or scleral icterus), ASL/ALT elevations, quality of life (MOS-HIV physical and mental summary scores), and adherence (MACS adherence questionnaire) were described.
Summary of results
Although the proportion of patients with hyperbilirubinemia at any time throughout the study was 44%, the proportion of ATV/r patients with hyperbilirubinemia at any single visit was between 12.5% and 21.6%. Of patients with hyperbilirubinemia at any time, 11% had grades 2-4 treatment-related jaundice or scleral icterus at any time (0 of patients without hyperbilirubinemia), and 4% had grades 3-4 AST/ALT elevations at any time (3% of patients without hyperbilirubinemia). Quality of life and adherence in patients without and with hyperbilirubinemia. Table 1 .
Conclusions
Hyperbilirubinemia, while common in patients on ATV/ r at any time through 96 weeks in the CASTLE study, 
